Published guidance, NICE advice and quality standards | Guidance

Showing 241 to 250 of 797

Sort by

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer	TA784	20 April 2022	20 April 2022
Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal)	TA785	20 April 2022	20 April 2022
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma	TA783	13 April 2022	13 April 2022
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer	TA781	30 March 2022	30 March 2022
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal)	TA782	30 March 2022	30 March 2022
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma	TA780	24 March 2022	24 March 2022
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency	TA779	16 March 2022	16 March 2022
Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal)	TA774	9 March 2022	9 March 2022
Empagliflozin for treating chronic heart failure with reduced ejection fraction	TA773	9 March 2022	9 March 2022
Dapagliflozin for treating chronic kidney disease	TA775	9 March 2022	9 March 2022